| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acquired Resistance to 17-DMAG is Mediated by Reduced NQO1 in Lung Cancer with ALK Translocation
|
Lee, J.C.
|
|
|
24 |
S1 |
p. i21
|
article
|
| 2 |
A Diverse Induction of Apoptosis by Trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2 + /ER-) Breast Cancer Cells
|
Atmaca, H.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 3 |
A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
|
Pollyea, D.
|
|
|
24 |
S1 |
p. i33
|
article
|
| 4 |
AMP-224, a Fusion Protein that Targets PD-1
|
Smothers, F.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 5 |
A New Paradigm for Cancer Therapy: A Targeted Systemic Preventive/Therapeutic Approach
|
Crawford, S.
|
|
|
24 |
S1 |
p. i18
|
article
|
| 6 |
A Novel HER3/ERBB3 Driver Mutation in Non-Small Cell Lung Cancer
|
Umelo, I.A.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 7 |
Anticancer Activity of Benzimidazole Derived Isothioureas in Vitro
|
Koronkiewicz, M.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 8 |
Anticancer Drug and Selenium-Enriched Spirulina Platensis: A New Concept for Drug Delivery and High Anti-Proliferative Activitym.
|
Riva, P.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 9 |
Anticancer Effect of Green Tea Nanoextract is Associated with Modifications in Methylation of Genes Involved in Proliferation and Apoptosis
|
Zalietok, S.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 10 |
Antimetastatic Activity of Atu027, a Liposomal Sirna Formulation, Targeting Protein Kinase N3: Final Results of a Phase I Study
|
Strumberg, D.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 11 |
A Phase 1B Study of Brivanib in Combination with 5FU/LV and FOLFIRI in Patients with Advanced or Metastatic Gastro-Intestinal Malignancies
|
Hollebecque, A.
|
|
|
24 |
S1 |
p. i33
|
article
|
| 12 |
A Phase II Clinical Trial of ENMD-2076 in Metastatic Triple-Negative Breast Cancer: Translating a P53-Based Biomarker from Bench to Bedside
|
Diamond, J.R.
|
|
|
24 |
S1 |
p. i36
|
article
|
| 13 |
A Potent Thioxanthone which Induces Autophagy and Cell Death in a Melanoma Cell Line
|
Lima, R.T.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 14 |
A Proof-of-Principle Histone Deacetylase Inhibitor Trial in Resectable Aerodigestive Tract Cancer: Intratumoral Drug Levels and Biomarker Responses
|
Dragnev, K.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 15 |
ARGX-110: A Neutralizing, Humanized Monoclonal Antibody to the Human CD70 Antigen with Enhanced ADCC Properties
|
Silence, K.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 16 |
Author Index
|
|
|
|
24 |
S1 |
p. i37-i39
|
article
|
| 17 |
AUY922, a Novel HSP90 Inhibitor Effective Against ABC-DLBCL and MALT Lymphoma Cells Harboring Genetic Alteration-Associated NF-κB Activation
|
Chen, L.T.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 18 |
BCRP/ABCG2 Expression is Involved in the Sensitivity of HCC Cells to Sorafenib
|
Chen, Y.J.
|
|
|
24 |
S1 |
p. i27
|
article
|
| 19 |
Biomarkers for the Prediction of the Efficacy of Bevacizumab in Taiwanese Metastatic Colorectal Cancer Patients
|
Lin, S.R.
|
|
|
24 |
S1 |
p. i27
|
article
|
| 20 |
Bone Marrow-Derived Mesenchymal Stem Cells Promote Growth and Angiogenesis of Breast and Prostate Tumors
|
Zhang, T.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 21 |
Carboplatin and ALDH1+ Breast Cancer Stem Cells: Unseen Facts
|
Veena, S.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 22 |
Challenges to PDTX Models in Drug Development
|
Eckhardt, S.G.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 23 |
Co-Existence of Cyclin D1 and VEGF Expression is a Poor Prognostic Factor for UICC Stage I-III Colorectal Cancer Patients
|
Wang, J.Y.
|
|
|
24 |
S1 |
p. i27
|
article
|
| 24 |
Colorectal Cancer Xenopatients: A Preclinical Platform for Precision Medicine
|
Trusolino, L.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 25 |
Contribution of Monocarboxylate Transporters to the Aggressive Phenotype of Breast Cancer
|
Morais-Santos, F.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 26 |
Cooperation of Senescence with Self-Renewal in PA1 Embryonal Carcinoma Cells Treated with Etoposide
|
Erenpreisa, J.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 27 |
Design and Clinical Development of Antibody Drug Conjugates
|
Lutzker, S.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 28 |
Development of MPDL3280A, an Anti-PD-L1 Antibody Engineered for Enhanced Efficacy and Safety
|
Chen, D.S.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 29 |
Development of Quantitative Gastrointestinal Carcinoma (GEC and CRC) SRM Assays for Use in FFPE Tumor Tissues
|
Hembrough, T.A.
|
|
|
24 |
S1 |
p. i27
|
article
|
| 30 |
Development of Therapeutic Cytotoxic Immunotoxin to Histocytic Lymphoma Cells
|
Nand, K.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 31 |
DNA Methyltransferase 1 Inhibitors can Enhance the Effect of Chemotherapeutic Agents in Colorectal Cancer Cells
|
Flis, S.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 32 |
Double Targeting for Ewing Sarcoma Chemotherapy
|
Malvy, C.P.
|
|
|
24 |
S1 |
p. i18
|
article
|
| 33 |
Downregulation of CD44 Leads to Therapeutic Resistance and Poor Prognosis in Non-Small Cell Lung Cancer
|
Choi, C.M.
|
|
|
24 |
S1 |
p. i27
|
article
|
| 34 |
Drug Index
|
|
|
|
24 |
S1 |
p. i40
|
article
|
| 35 |
Editorial board
|
|
|
|
24 |
S1 |
p. ii-iii
|
article
|
| 36 |
Effects of Tasisulam Sodium on the Pharmacokinetics of Tolbutamide in Patients with Advanced Solid Tumours
|
Twelves, C.J.
|
|
|
24 |
S1 |
p. i33
|
article
|
| 37 |
Endothelial Cell-Derived Targets that Induce the Cancer Stem Cell Phenotype
|
Ellis, L.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 38 |
Establishment of Novel Preclinical Melanoma Models Resistant to Vemurafenib
|
Robichon, C.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 39 |
Exploitation of MCTS /BSG as Therapeutic Targets in Lung Cancer
|
Granja, S.
|
|
|
24 |
S1 |
p. i19
|
article
|
| 40 |
Exploiting Glutamine Addiction of Tumor Cells for Selective and Improved Delivery of Chemotherapic Drugs in Cancer Treatment
|
Neto, M.D.S.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 41 |
Final Results of Phase I Study of the Oral Class I PI3K Inhibitor CH5132799 in Patients with Advanced Solid Tumours
|
Suder, A.
|
|
|
24 |
S1 |
p. i33
|
article
|
| 42 |
Galeterone: A Triple Action Drug for the Treatment of Castration-Resistant Prostate Cancer: ARMOR1 Results
|
Senderowicz, A.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 43 |
Gene Translocations as Targets for Treatment
|
Janne, P.A.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 44 |
Green Tea Polyphenols Enhance Therapeutic Efficacy of Anticancer Drugs as to Drug-Resistant Experimental Tumors
|
Chekhun, V.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 45 |
Gut Commensal Bacteria Determine Cancer Response to Treatment by Modulating Systemic Inflammation
|
Trinchieri, G.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 46 |
Hematology and Drug Development in the 'Targeted Therapy' Area
|
Ribrag, V.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 47 |
Histone Deacetylase (HDAC) Inhibition in Hepatocellular Cancer
|
Chan, S.L.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 48 |
Human Cancer Cells Isolated from Ascites as Models to Optimize the Use of Targeted Anticancer Agents in Ovarian Cancer
|
Banerji, U.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 49 |
Hypoxia Signaling, Phi Regulation & Tumor Metabolism. Novel Therapeutic Approaches
|
Pouysségur, J.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 50 |
Identification of Anti-WNT2 Mouse Monoclonal Antibody as a Targeted Anticancer Therapy in Esophageal Squamous Cell Carcinoma
|
Chen, J.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 51 |
Immunomodulatory Activity of SGI-110, a Second Generation Hypomethylating Agent
|
Maio, M.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 52 |
Implementing Appropriate Phase I Study Designs in the Era of Combined Therapies
|
Schoenborn-Kellenberger, O.
|
|
|
24 |
S1 |
p. i34
|
article
|
| 53 |
Influence of Cancer Associated Fibroblast (CAF) on Human Breast Cancer Cells in an in Vitro Co-Cultivation Model of Breast Cancer
|
Sreelatha, K.H.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 54 |
Inhibition of Casein Kinase II (CK2) Enhances Ikaros Tumor Suppressor Activity and Shows Therapeutic Efficacy in a Preclinical Leukemia Model
|
Dovat, S.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 55 |
Inhibition of Notch Pathway in Non-Small Cell Lung Cancer
|
Nikolakopoulos, A.
|
|
|
24 |
S1 |
p. i21
|
article
|
| 56 |
Inhibitor of ATR (Ataxia Telangiectasia and Rad 3 Related) Kinase
|
Plummer, E.R.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 57 |
Interaction between an in Vitro Selected Rotavirus and Several Heat Shock Proteins (HSPS) During the Infection Process in Cell Lines U-937 and REH
|
Hernández, J.C.
|
|
|
24 |
S1 |
p. i18
|
article
|
| 58 |
JAK2 Inhibitors: Present and Future
|
Vainchenker, W.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 59 |
Marine Alkaloid Monanchocidin: A Proteomic-Based Screening of Protein Targets in Cisplatin-Resistant Tumor Cells
|
Dyshlovoy, S.A.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 60 |
Metformin Promotes Cancer Cells Death, Inhibits PGP Expression and Sensitize MDR Leukemic Cells to the Effects of Imatinib Mesylate
|
Curvello, R.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 61 |
Mitochondrial Metabolic Reprogramming of Melanoma Cells Exposed to BRAFV600E Inhibitor
|
Kluza, J.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 62 |
Mutation-Selective IDH Inhibitors Mediate Histone and Dna Methylation Changes
|
Agresta, S.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 63 |
New Toxicities of Immune Checkpoint Modulators
|
Hodi, F.S.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 64 |
Next-Generation Sequencing and Phase I Clinical Trials in Cancer
|
Janku, F.
|
|
|
24 |
S1 |
p. i10
|
article
|
| 65 |
Nivolumab (Anti-Programmed Death-1 [PD-1]; BMS-936558) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers
|
Feltquate, D.M.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 66 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 67 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 68 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 69 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 70 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 71 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 72 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 73 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 74 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 75 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 76 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 77 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 78 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 79 |
No Abstract Available
|
|
|
|
24 |
S1 |
p. i7
|
article
|
| 80 |
Nov C-TER: A Novel VEGF-Independent Anti-Angiogenic Agent with a Promising Preclinical Anti-Tumor Efficacy
|
Rixe, O.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 81 |
Novel Phytochemical to Target BRCA2 Related Prostate Cancer
|
Priya, S.
|
|
|
24 |
S1 |
p. i23
|
article
|
| 82 |
Off-Target Activity of Lapatinib Sensitizes Triple-Negative Breast Cancer Cells to Proteasome Inhibitors Through Activation of NF-κB in a SFK-Dependent Manner
|
Huang, W.C.
|
|
|
24 |
S1 |
p. i21
|
article
|
| 83 |
Organizers
|
|
|
|
24 |
S1 |
p. i5
|
article
|
| 84 |
Ovarian Avatar Models Predictive of Platinum Response in Ovarian Cancer Patients
|
Weroha, S.J.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 85 |
Patient Selection for Anti-Egfviii Therapies in Glioblastoma Multiforme (GBM): Use of Circulating Tumor DNA
|
Rixe, O.
|
|
|
24 |
S1 |
p. i27
|
article
|
| 86 |
Personalized Medicine by Analyzing Circulating DNA: Application to the Management Care of Colorectal Cancer Patients
|
Mouliere, F.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 87 |
Pharmacological Stabilization of Commd1 Mediated by CIGB-552 Regulates NF-KB/Oxidative Stress Signaling and Inhibits Lung Cancer Cells Growth
|
Oliva, B.M.
|
|
|
24 |
S1 |
p. i21
|
article
|
| 88 |
Phase I Clinical and Pharmacological Study of Cetugex, a Novel Anti-EGFR Monoclonal Antibody with an Optimized Antibody Dependent Cellular Cytotoxicity
|
de Dosso, S.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 89 |
Phase I Trial of RAD001 (Everolimus) in Combination with Radiotherapy in Non-Small Cell Lung Cancer
|
Deutsch, E.
|
|
|
24 |
S1 |
p. i9
|
article
|
| 90 |
Phenotypic Screening for Kinase Targets Using Small Molecule Inhibitors with Proven Cell Penetration
|
Winkler, J.
|
|
|
24 |
S1 |
p. i18
|
article
|
| 91 |
PI3K/AKT Activation and Response in Phase IB: AKT Inhibitor GDC-0068 with Docetaxel (D) Or MFOLFOX6 (F) in Refractory Solid Tumors
|
Meng, R.
|
|
|
24 |
S1 |
p. i33
|
article
|
| 92 |
P53 Modulates Trabectedin Mediated Cytotoxicity in Glioblastoma Multiforme Cells (U-87MG and T98G)
|
Bozkurt, E.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 93 |
Potential Therapeutic Implications of Altered Atm and P53 Status in Solid Tumours
|
Bebb, D.G.
|
|
|
24 |
S1 |
p. i27
|
article
|
| 94 |
Potent Inhibition of Human Liposarcoma Growth and Survival by Novel Modulators of the MDM2-P53 Interaction
|
Wagner, A.J.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 95 |
Practical Applications of Avatar Mouse Models in Cancer Drug Development and Treatment
|
Hidalgo, M.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 96 |
Preclinical Characterization of E7438, a Potent, Selective EZH2 Inhibitor with Robust Antitumor Activity Against EZH2 Mutated NHL Xenografts in Mice
|
Keilhack, H.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 97 |
Prognostic Significance of Cytokeratin Markers in Breast Cancer – A Meta Analysis
|
Barak, V.
|
|
|
24 |
S1 |
p. i27
|
article
|
| 98 |
Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Refractory Cancer Patients: Shiva Design
|
Le Tourneau, C.
|
|
|
24 |
S1 |
p. i36
|
article
|
| 99 |
Rapid Validation of Cancer Genes and Drug Targets in Genetically Engineered Mouse Models of Cancer
|
Huijbers, I.J.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 100 |
Regulation of Ether À-Go-Go-1 Potassium Channel (EAG1) Gene Expression by Serum and TGF-Alpha in Human Liver Cancer Cells
|
Acuña, M.I.
|
|
|
24 |
S1 |
p. i21
|
article
|
| 101 |
Reversal of Resistance of EGFR Tyrosine Kinase Inhibitor (Gefitinib) by EGFR T790M Specific SiRNA
|
Lee, C-T.
|
|
|
24 |
S1 |
p. i19-i20
|
article
|
| 102 |
Rigosertib is a More Effective Radiosensitizer than Cisplatin in Concurrent Chemo-Radiation Treatment of Cervical Carcinoma, In Vitro and In Vivo
|
Agoni, L.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 103 |
Selection of Indications for Pimasertib in Phase II Testing Based on Signals of Activity and Rational Choice of Target Disease
|
Massimini, G.
|
|
|
24 |
S1 |
p. i33
|
article
|
| 104 |
Similar PI3K and RTK-RAS Status in Patient Derived Colorectal Cancer-Xenografts and Patients
|
Nunes, M.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 105 |
Small Molecular Subsets in Phase I Studies
|
Siu, L.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 106 |
Sponsors, supporters and exhibitors
|
|
|
|
24 |
S1 |
p. i6
|
article
|
| 107 |
Study of a Cohort of Patients with Metastatic Melanoma Treated with Ipilimumab
|
Roussel, A.
|
|
|
24 |
S1 |
p. i36
|
article
|
| 108 |
Table of Contents
|
|
|
|
24 |
S1 |
p. iv
|
article
|
| 109 |
Targeted Drug Development in Pediatric Cancer Despite a Low Frequency of Tumor Driving Mutations
|
Molenaar, J.J.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 110 |
Targeting Lactate Metabolism in Cancer
|
Critchlow, S.E.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 111 |
Targeting RAF Kinases in BRAF and KRAS Mutant Cancers
|
Luo, J.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 112 |
Targeting the P53 Tumor Suppressor Pathway for Improved Cancer Therapy
|
Wiman, K.G.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 113 |
Targeting to Tumor-Associated Antigen ENO1 Provides Preventive and Therapeutic Effects on Disease Progression of Lung Cancer
|
Shih, N.Y.
|
|
|
24 |
S1 |
p. i27
|
article
|
| 114 |
Targeting Tumor Cell Metabolism: Restriction of Glucose Consumption Sensitizes Multidrug Resistant (MDR) Leukemia Cells to the Effects of Imatinib Mesylate
|
Ramos, S.P.
|
|
|
24 |
S1 |
p. i30
|
article
|
| 115 |
The Evaluation of Selumetinib a MEK-Inhibitor with and without the Addition of Erlotinib in KRAS Mutated Non-Small Cell Lung Cancer
|
Carter, C.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 116 |
The Impact of the FDA's Companion Diagnostic Guidelines on Translation of Molecular Diagnostic Tests
|
Lynch, J.A.
|
|
|
24 |
S1 |
p. i27
|
article
|
| 117 |
The Molecular Consequences of Inhibiting Fatty Acid Synthase in Cancer Cells
|
Wooster, R.F.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 118 |
Title Page
|
|
|
|
24 |
S1 |
p. i
|
article
|
| 119 |
TLR-Ligand Peptide Conjugates for Superior Therapeutic Vaccination Against Immunogenic Cancers
|
Melief, J.M.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 120 |
Tumor Heterogeneity: Is it Really a Problem?
|
Voest, E.E.
|
|
|
24 |
S1 |
p. i7
|
article
|
| 121 |
Vinorelbine Activates Downstream Targets of Notch Signaling on Huvec Cells
|
Mavroeidis, L.
|
|
|
24 |
S1 |
p. i21
|
article
|
| 122 |
Winther: A Study to Select Rational Therapeutics Based On the Analysis of Tumor and Matched Normal Tissue Biopsies in Subjects with Advanced Malignancies
|
Soria, J.C.
|
|
|
24 |
S1 |
p. i7
|
article
|
Journal description